Mark A. Varney

Neurolixis, Inc. is an early-stage biopharmaceutical company that focuses on discovering and developing novel drugs for the treatment of central nervous system disorders such as Parkinson's disease, Rett syndrome, depression, and pain. Neurolixis is based in Dana Point, CA. The private company is developing a platform of early-stage drug candidates that target serious CNS diseases with unmet medical needs and a sizable market opportunity. The company's compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism," which enables drugs to more precisely target specific brain regions controlling CNS disorders. The company was founded by Mark A. Varney and Adrian Newman-Tancredi, and Adrian Newman-Tancredi has been the CEO since incorporation.

Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA.